Halfdanarson Thorvardur R, Strosberg Jonathan R
Mayo Clinic, Division of Medical Oncology, 200 First Street SW, Rochester, MN 55905, USA.
Curr Clin Pharmacol. 2015;10(4):305-10. doi: 10.2174/1574884710666151020100211.
Neuroendocrine tumors (NETs) are relatively uncommon. They typically arise in the gastrointestinal tract and lungs, and their incidence seems to be rising. Most patients have advanced disease at the time of diagnosis and many more will relapse after surgery. There is thus a great need for improvements in therapy for advanced neuroendocrine tumors. This article reviews the current therapy for both pancreatic NETs and non-pancreatic gastrointestinal NETs, and discusses recent advances in NET management with an emphasis on targeted therapy.
神经内分泌肿瘤（NETs）相对不常见。它们通常起源于胃肠道和肺部，而且其发病率似乎在上升。大多数患者在诊断时已处于疾病晚期，还有更多患者术后会复发。因此，迫切需要改进晚期神经内分泌肿瘤的治疗方法。本文综述了胰腺NETs和非胰腺胃肠道NETs的当前治疗方法，并讨论了NET管理方面的最新进展，重点是靶向治疗。
